Guoqing Li

7598250, Oct 6, 2009

Aug 4, 2004

10/911030

Jared N. Cumming - Garwood NJ, US
Ying Huang - East Brunswick NJ, US
Guoqing Li - Belle Mead NJ, US
Ulrich Iserloh - Hoboken NJ, US
Andrew Stamford - Chatham Township NJ, US
Corey Strickland - Martinsville NJ, US
Johannes H. Voigt - Union NJ, US
Yusheng Wu - New York NY, US
Jianping Pan - Monmouth Junction NJ, US
Tao Guo - Dayton NJ, US
Douglas W. Hobbs - Yardley PA, US
Thuy X. H. Le - Monmouth Junction NJ, US
Jeffrey F. Lowrie - Pennington NJ, US

Schering Corporation - Kenilworth NJ

A61K 31/506
A61K 31/496
C07D 403/12
C07D 401/14
C07D 405/14
C07D 409/14
C07D 417/14

51425214, 51425401, 51425405, 544295, 544357, 544363, 544364, 544365, 544368, 544369, 544370, 544371, 544372, 546208, 546221, 5462784, 548204, 5483241, 548518, 548556, 548452, 548512

Disclosed are novel compounds of the formulaAlso disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula I. Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.

20120183563, Jul 19, 2012

Oct 6, 2010

13/392297

Jack D. Scott - Scotch Plains NJ, US
Andrew W. Stamford - Chatham NJ, US
Eric J. Gilbert - Scotch Plains NJ, US
Jared N. Cumming - Garwood NJ, US
Ulrich Iserloh - Hoboken NJ, US
Jeffrey A. Misiaszek - Somerset NJ, US
Guoqing Li - Belle Mead NJ, US

A61K 31/549
C07D 285/18
C07D 417/14
C07D 471/04
C07D 495/04
A61K 31/55
A61K 39/395
A61K 39/00
A61P 29/00
A61P 31/04
A61P 37/04
A61P 5/50
A61P 25/28
A61P 25/16
A61P 25/00
A61P 3/10
C07D 417/04
A61P 7/04
A61P 7/00
C07D 417/12

4241721, 544 8, 5142225, 514215, 4241841

In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): (I) and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R, R, R, R, R, R, ring A, ring B, m, n, p, -L-,L-, and L- is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (Aβ) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers disease, are also disclosed.

20230008022, Jan 12, 2023

Nov 25, 2019

17/295497

Dane CLAUSEN - Kenilworth NJ, US
Ping CHEN - Kenilworth NJ, US
Xavier FRADERA - Boston MA, US
Liangqin GUO - Kenilworth NJ, US
Yongxin HAN - Boston MA, US
Shuwen HE - Fanwood NJ, US
Xianhai HUANG - Warren NJ, US
Joseph KOZLOWSKI - Princeton NJ, US
Guoqing LI - Kenilworth NJ, US
Theodore A. MARTINOT - Southborough MA, US
Alexander PASTERNAK - Boston MA, US
Andreas VERRAS - New York NY, US
Li XIAO - Kenilworth NJ, US
Wensheng YU - Kenilworth NJ, US
Rui ZHANG - Kenilworth NJ, US
- Rahway NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 231/56
C07D 491/052
C07D 231/54
A61K 31/496
C07D 401/12
C07D 401/14
C07D 413/12
A61K 31/5377
C07D 498/10
C07D 491/107
C07D 498/08
C07D 471/10
C07D 403/12
C07D 405/12
C07D 498/04
C07D 487/04
C07D 487/10
A61K 31/541
C07D 413/14

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

20210395240, Dec 23, 2021

Oct 28, 2019

17/287256

Dane CLAUSEN - Kenilworth NJ, US
- Rahway NJ, US
Liangqin Guo - Monroe Township NJ, US
Yongxin Han - Needham MA, US
Shuwen He - Fanwood NJ, US
Joseph Kozlowski - Princeton NJ, US
Guoqing Li - Belle Mead NJ, US
Theodore A. Martinot - Southborough MA, US
Alexander Pasternak - Jamaica Plain MA, US
David Sloman - Newton MA, US
Li Xiao - Cranbury NJ, US
Wensheng Yu - Edison NJ, US
Rui Zhang - Plainsboro NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 413/14
C07D 401/14

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

20180193314, Jul 12, 2018

Jun 6, 2016

15/815212

- Rahway NJ, US
Walter Won - Alpine NJ, US
Michael Berlin - Flemington NJ, US
Pauline Ting - New Providence NJ, US
Guoqing Li - Belle Mead NJ, US
Dong Xiao - Somerset NJ, US
Hongwu Wang - Westfield NJ, US
Robert Aslanian - Rockaway NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

A61K 31/4162
A61K 31/519
A61K 31/497
A61P 25/00

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof, wherein: “Z”, Rand Rare defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

20170173035, Jun 22, 2017

May 4, 2015

15/309533

- Rhhway NJ, US
Shu-Wei Yang - Edison NJ, US
Mihir Mandal - Westfield NJ, US
Jing Su - Scotch Plains NJ, US
Guoqing Li - Belle Mead NJ, US
Weidong Pan - Hillsborough NJ, US
Haiqun Tang - Belle Mead NJ, US
Reynalda DeJesus - East Brunswick NJ, US
Jianping Pan - Monmouth Junction NJ, US
William Hagmann - Westfield NJ, US
Li Xiao - Cranbury NJ, US
Alexander Pasternak - Princeton NJ, US
Yuhua Huang - Westfield NJ, US
Shuzhi Dong - Plainsboro NJ, US
Dexi Yang - Livingston NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

A61K 31/546
A61K 31/407
A61K 31/496
A61K 31/43
A61K 31/427
A61K 31/44
A61K 31/41

The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

20170174693, Jun 22, 2017

Dec 20, 2016

15/384429

Raphaelle Berger - New York NY, US
Yi-Heng Chen - Whippany NJ, US
Guoqing Li - Belle Mead NJ, US
Joie Garfunkle - Kriens, CH
Shouwu Miao - Edison NJ, US
Subharekha Raghavan - Teaneck NJ, US
Cameron J. Smith - Montgomery Village MD, US
John Stelmach - Westfield NJ, US
Alan Whitehead - Scotch Plains NJ, US
Rui Zhang - Plainsboro NJ, US
Yong Zhang - West Windsor NJ, US
Jianmin Fu - Beijing, CN
Gang Ji - Beijing, CN
Falong Jiang - Beijing, CN

C07D 487/04
A61K 31/519
C07D 519/00
A61K 45/06

The invention provides compounds of the Formula (I)or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R, R, R, R, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

20160333021, Nov 17, 2016

Jan 16, 2015

15/110431

- Rahway NJ, US
Haifeng Tang - Metuchen NJ, US
Li Xiao - Cranbury NJ, US
Jing Su - Scotch Plains NJ, US
Guoqing Li - Belle Mead NJ, US
Shu-Wei Yang - Edison NJ, US
Weidong Pan - Hillsborough NJ, US
Haiqun Tang - Belle Mead NJ, US
Reynalda DeJesus - East Brunswick NJ, US
Jacqueline Hicks - Scotch Plains NJ, US
Matthew Lombardo - Flemington NJ, US
Hong Chu - Livingston NJ, US
William Hagmann - Westfield NJ, US
Alex Pasternak - Princeton NJ, US
Xin Gu - Scotch Plains NJ, US
Jinlong Jiang - Scotch Plains NJ, US
Shuzhi Dong - Plainsboro NJ, US
Clare London - Chatham NJ, US
Dipshikha Biswas - Woodbridge NJ, US
Katherine Young - Metuchen NJ, US
David N. Hunter - Scotch Plains NJ, US
Zhiqiang Zhao - Scotch Plains NJ, US
Dexi Yang - Livingston NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 491/048
A61K 31/41
A61K 45/06
A61K 31/407
A61K 31/197
C07D 405/12
A61K 31/5377
C07D 403/10
A61K 31/4192
A61K 31/496
C07D 401/10
A61K 31/454
A61K 31/4439
C07D 409/10
C07D 417/10
A61K 31/427
C07D 405/14
C07D 413/10
A61K 31/422
A61K 31/506
A61K 31/497
A61K 31/4178
A61K 31/501
A61K 31/4155
C07D 471/04
A61K 31/437
C07D 417/14
C07D 401/14
C07D 487/04
A61K 31/5025
A61K 31/4245
A61K 31/541
C07D 401/04
C07D 413/14
A61K 31/55
C07D 471/10
C07D 257/04

The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.